Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes

Drug Des Devel Ther. 2016 Dec 15:10:4073-4078. doi: 10.2147/DDDT.S117080. eCollection 2016.

Authors

Ali T Taher¹, John B Porter², Antonis Kattamis³, Vip Viprakasit⁴, M Domenica Cappellini⁵

Affiliations

¹ Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
² Department of Haematology, University College London, London, UK.
³ First Department of Pediatrics, University of Athens, Athens, Greece.
⁴ Department of Pediatrics and Thalassemia Center, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
⁵ Department of Internal Medicine, Università di Milano, Ca Granda Foundation IRCCS, Milan, Italy.

No abstract available

Publication types

Comment

MeSH terms

Benzoates
Chelation Therapy*
Deferoxamine*
Drug Therapy, Combination
Humans
Iron / therapeutic use
Iron Chelating Agents
Pyridones
Syndrome
Thalassemia / chemically induced
Triazoles

Substances

Benzoates
Iron Chelating Agents
Pyridones
Triazoles
Iron
Deferoxamine